A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

NCT05406401 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Large B-Cell, Diffuse (DLBCL)

Interventions

BIOLOGICAL: Zilovertamab Vedotin
DRUG: Cyclophosphamide
DRUG: Doxorubicin
BIOLOGICAL: Rituximab
BIOLOGICAL: Rituximab Biosimilar
DRUG: Prednisone
DRUG: Prednisolone

Sponsor

Merck Sharp & Dohme LLC